11 Fastest Growing Penny Stocks to Buy Right Now

Page 2 of 10

9. TriSalus Life Sciences, Inc. (NASDAQ:TLSI)

On March 6, 2026, Canaccord analyst William Plovanic lowered the price target on TriSalus Life Sciences, Inc. (NASDAQ:TLSI) to $7 from $12 previously and maintained a Buy rating. William Plovanic said Q4 results came in line with the company’s preannouncement and that guidance was reiterated, with 2026 expected to be back-end loaded as the company doubles its sales force.

On March 5, 2026, TriSalus Life Sciences, Inc. (NASDAQ:TLSI) reported fourth-quarter EPS of (21c) versus consensus of (14c) and revenue of $13.205M compared with $8.261M in the prior year. CEO Mary Szela pointed to “strong commercial performance,” citing growing clinical adoption of the TriNav product suite and the company’s proprietary PEDD platform across multiple solid tumor indications. Szela added that TriSalus Life Sciences, Inc. (NASDAQ:TLSI) exceeded its 2025 revenue growth guidance as the company expanded the TriNav platform beyond liver indications.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) expects FY26 revenue of $60M to $62M compared with the consensus of $60.34M.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) develops drug delivery technology platforms and immuno-oncology therapeutics aimed at improving outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.

Page 2 of 10